- Home
- LGVN vs PRPO Comparison
LGVN vs PRPO Comparison
Compare LGVN & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- PRPO
- Stock Information
- Founded
- LGVN 2014
- PRPO N/A
- Country
- LGVN United States
- PRPO United States
- Employees
- LGVN N/A
- PRPO 57
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- LGVN Health Care
- PRPO Industrials
- Exchange
- LGVN Nasdaq
- PRPO Nasdaq
- Market Cap
- LGVN 30.0M
- PRPO 9.5M
- IPO Year
- LGVN 2021
- PRPO N/A
- Fundamental
- Price
- LGVN $2.05
- PRPO $6.59
- Analyst Decision
- LGVN Strong Buy
- PRPO
- Analyst Count
- LGVN 2
- PRPO 0
- Target Price
- LGVN $8.00
- PRPO N/A
- AVG Volume (30 Days)
- LGVN 393.9K
- PRPO 7.9K
- Earning Date
- LGVN 11-08-2024
- PRPO 11-11-2024
- Dividend Yield
- LGVN N/A
- PRPO N/A
- EPS Growth
- LGVN N/A
- PRPO N/A
- EPS
- LGVN N/A
- PRPO N/A
- Revenue
- LGVN $1,229,000.00
- PRPO $16,719,999.00
- Revenue This Year
- LGVN $161.78
- PRPO $75.18
- Revenue Next Year
- LGVN $8.62
- PRPO N/A
- P/E Ratio
- LGVN N/A
- PRPO N/A
- Revenue Growth
- LGVN 39.34
- PRPO 52.61
- 52 Week Low
- LGVN $0.77
- PRPO $4.31
- 52 Week High
- LGVN $23.90
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- LGVN 52.20
- PRPO 52.82
- Support Level
- LGVN $1.76
- PRPO $6.42
- Resistance Level
- LGVN $2.26
- PRPO $6.99
- Average True Range (ATR)
- LGVN 0.12
- PRPO 0.33
- MACD
- LGVN 0.05
- PRPO -0.04
- Stochastic Oscillator
- LGVN 58.00
- PRPO 69.91
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.